Archives
-
SB-3CT: A Gelatinase Inhibitor for ECM Studies
2026-09-10
SB-3CT is a mechanism-based gelatinase inhibitor for separating MMP-2 and MMP-9 activity from broader extracellular-matrix effects. This workflow connects biochemical validation with tumor metastasis research, perineuronal-net remodeling, and neuroprotection in cerebral ischemia while emphasizing solvent control and interpretation limits.
-
Cy3 NHS Ester (Non-Sulfonated) Protocol Guide
2026-09-10
Cy3 NHS ester (non-sulfonated) provides a water-insoluble NHS ester for fluorescent labeling of accessible amino groups on proteins, peptides, and amino-modified oligonucleotides. It is appropriate when DMSO or DMF can be tolerated, but it is not the first choice for delicate biomolecules requiring entirely aqueous labeling or for long-term storage of prepared dye solutions.
-
CD40–STING–TRAF2 Signaling in ESCC TLS
2026-09-09
A 2025 Cancer Gene Therapy study identifies tertiary lymphoid structures as favorable prognostic features in treatment-naïve esophageal squamous cell carcinoma and highlights IRF4-positive tumor-infiltrating B cells as a central immune population. Its mechanistic data support a model in which CD40 and STING compete for TRAF2, shaping non-canonical NF-κB signaling, STING post-translational regulation, and B-cell activation.
-
DMH1: An ALK2 Inhibitor for Organoid Assays
2026-09-09
DMH1 enables selective BMP-pathway perturbation across pancreatic ductal organoid workflows and non-small cell lung cancer research. This guide connects pathway verification, organoid quality control, migration assays, and practical troubleshooting without assuming that every phenotype is BMP-dependent.
-
Angiotensin III: RAAS Workflow and Assay Guide
2026-09-08
Build reproducible RAAS experiments with Angiotensin III, from aldosterone and renin measurements to AT1/AT2 receptor pathway studies. A recent binding study also suggests a carefully controlled route for extending this cardiovascular research peptide into spike–host receptor assays without confusing biochemical findings with antiviral efficacy.
-
Developmental SSRI Exposure and Mu Opioid Signaling
2026-09-08
A 2026 Columbia University dissertation shows that developmental fluoxetine exposure produces persistent, selective deficits in effortful motivation in adolescent and adult mice, while reward liking and learning remain comparatively intact. The work further identifies nucleus accumbens mu opioid receptors as a potentially actionable circuit target, because pharmacological antagonism and viral knockdown improved motivational performance whereas additional SSRI treatment did not.
-
ATRX Loss Sensitizes High-Grade Glioma to PDGFR Inhibitors
2026-09-07
The reference study shows that ATRX-deficient high-grade glioma cells are disproportionately sensitive to several receptor tyrosine kinase and PDGFR inhibitors, including when treatment is combined with temozolomide. Its main translational contribution is to connect ATRX status with drug-response interpretation, while highlighting the need for genotype-aware analysis of RTK inhibitor studies.
-
Mianserin Hydrochloride: Evidence from a Clinical Trial
2026-09-07
Coppen and colleagues evaluated mianserin hydrochloride against amitriptyline using randomized treatment allocation, blinded depression ratings, systematic side-effect monitoring, and serial plasma measurements. The study found similar antidepressant activity, a higher side-effect burden with amitriptyline, and no clear relationship between plasma mianserin concentration and therapeutic response.
-
Deuterium-Labeled Degarelix: Synthesis and Significance
2026-09-05
The reference study reports a practical route to deuterium-labeled degarelix acetate by introducing a D7 label into a naphthylalanine intermediate with D2O/D3PO4, followed by peptide assembly. The method provides a useful foundation for generating isotope-labeled internal standards for pharmacokinetic, absorption, distribution, metabolism, and excretion studies, while also illustrating the yield and validation challenges of multistep peptide synthesis.
-
MEHP Activates AhR in Mouse Ovarian Follicles
2026-09-04
The 2024 Biology of Reproduction study identifies the aryl hydrocarbon receptor as a functional mediator of mono(2-ethylhexyl) phthalate toxicity in mouse ovarian antral follicles. Pharmacological blockade with CH 223191 partially restored follicle growth, estrogen production, and estrogen-responsive gene expression, providing a causal framework for interpreting AhR involvement in reproductive toxicology.
-
HNRNPU K181 Lactylation Rewires Serine Metabolism
2026-09-04
This Advanced Science study identifies HNRNPU lysine 181 lactylation as a lactate-responsive mechanism that stabilizes HNRNPU, preserves PHGDH mRNA regulation, and activates serine biosynthesis in cervical cancer. The work connects a non-histone post-translational modification to tumor metabolism and evaluates pharmacological interference with this axis, while also highlighting the need for careful validation of mechanism and specificity.
-
Oligo (dT) 25 Beads: Practical mRNA Guide
2026-09-03
Oligo (dT) 25 Beads support selective polyA tail mRNA capture from eukaryotic total RNA or cell and tissue lysates, simplifying magnetic separation before cDNA synthesis or mRNA elution. They should not be used as a universal total-RNA cleanup method or for unbiased recovery of non-polyadenylated transcripts.
-
Hexamethonium Bromide for Autonomic Signaling Studies
2026-09-03
Use Hexamethonium Bromide to isolate ganglionic contributions from vascular, cardiac, and baroreflex responses in neuronal and cardiovascular assays. A practical workflow combines fresh solution preparation, sex-stratified telemetry, controlled blockade, and troubleshooting based on quantitative hypertension findings.
-
Drug-Sensitized Yeast for mTOR Inhibitor Discovery
2026-09-02
Breen and colleagues developed a genetically drug-sensitized Saccharomyces cerevisiae platform that detects TOR pathway inhibitors at markedly lower concentrations than wild-type yeast. The system distinguished known and candidate TOR inhibitors from compounds such as Canagliflozin that showed no TOR-dependent growth phenotype, providing a practical framework for early-stage mechanism-focused screening.
-
MLN4924 Workflow for NAE and CRL Studies
2026-09-02
MLN4924 gives cancer biology research a mechanistically defined way to inhibit NAE, suppress cullin-RING ligase activity, and track substrate accumulation. This workflow connects fast biochemical target engagement with cell-cycle assays and carefully controlled extensions into FBXW7–SPT6–ΔNp63 studies and xenograft biomarker development.